Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 11 of 36 / 848 articles
The visible cloud exhaled by a vaper is mostly water, propylene glycol, and glycerin. The invisible fraction—the ultrafine particles, the thermal degradation products—is where the risk lives. The cloud you see is not the cloud that matters.
As cigarette volumes decline, the financial viability of some companies is in question. A major bankruptcy would reshape the nicotine landscape overnight—disrupting supply chains, triggering litigation, and concentrating the market further.
The cardiovascular benefits of quitting begin within hours and accelerate over months. The heart is remarkably resilient. Some damage never fully reverses, but the recovery is faster and more complete than most smokers realize.
Writers smoke. The tradition extends from Sartre to Didion to Murakami. The cigarette is a tool of the craft—a cognitive enhancer, a ritual companion, a marker of the writer's identity. The tradition is romanticized and lethal.
School assemblies will be replaced by peer-produced TikTok content. Fear-based messaging by honest risk communication. Abstinence-only by harm reduction. The digital prevention future is more effective, more youth-centered, and more politically contested.
Future archaeologists will find cigarette filters in landfills, nicotine residue in sediments, and the isotopic signatures of tobacco in human remains. The material legacy of the cigarette era will persist for centuries. What story will it tell?
Age restrictions are only as good as their enforcement. The evidence on what works: compliance checks, retailer licensing with meaningful penalties, and restrictions on proxy purchasing. The evidence on what doesn't: warning letters and voluntary industry programs.
Smokers don't just experience stigma from others. They internalize it—believing they are weak, irresponsible, and morally deficient. Self-stigma is a stronger predictor of failed quit attempts than nicotine dependence severity.
The majority of quit attempts use no pharmacological support—cold turkey. The success rate: 3-5%. With NRT: 15-25%. The gap between the most common and the most effective methods is a public health failure of communication and access.
The nicotine policy landscape is stuck. Six evidence-based reforms—risk-proportionate regulation, honest communication, consumer participation, streamlined authorization, equitable taxation, and just transition—could unstick it.
Most vaping devices are designed to be replaced, not repaired. The right-to-repair movement has come for phones and tractors. It hasn't come for vapes—yet. A repairable vape would be better for consumers and better for the environment.
PMI pledges carbon neutrality by 2030. BAT has science-based targets. The pledges are real investments. They're also strategies for legitimacy. The nicotine industry's climate commitments reveal the complexity of corporate transformation.
Genetic variation affects response to every smoking cessation medication. CYP2A6 genotype predicts NRT response. CHRNA5 genotype predicts varenicline response. Personalized cessation—matching the treatment to the patient's genetics—is the future of quitting.
Actors smoke at elevated rates—driven by the culture of performance, the irregular hours, and the cigarette's role as a prop and a coping mechanism. The actor-smoker relationship illuminates the intersection of creativity, identity, and addiction.
Media literacy programs teach students to analyze and resist advertising. Applied to nicotine, they help young people recognize the marketing strategies that target them. Advertising literacy is one of the most promising—and underfunded—youth prevention approaches.
When tobacco leaves a rural community, what replaces it? The question has no single answer. Some communities find new crops, new industries, new identities. Others decline. The rural development challenge is the economic dimension of the tobacco transition.
The PMTA process costs $1-10 million per product. State licensing, age verification, and reporting requirements add thousands more. The compliance costs of nicotine regulation create a market accessible only to the largest corporations.
Nicotine use produces pleasure—and guilt about the pleasure. The combination of pleasure and guilt is psychologically destabilizing, making nicotine use simultaneously more appealing (the forbidden fruit) and more distressing (the shame).
Social support is one of the strongest predictors of cessation success. It's also one of the hardest things to provide through the healthcare system. The gap between the importance of social support and its availability is a central challenge of cessation.
Sweden has the lowest smoking rate in Europe—achieved not through abstinence but through snus, a reduced-risk oral product. The Swedish model is the strongest evidence for harm reduction. Can it be replicated elsewhere?
Disposable vapes are designed to be thrown away. A handful of startups and environmental initiatives are trying to change that—developing recycling systems for the lithium batteries, circuit boards, and plastics. The quest is difficult. It's also essential.
The major nicotine companies all claim to be transitioning to a 'smoke-free future.' The claims are partly true—and partly strategic. Understanding what's real and what's rhetoric is essential to evaluating the industry's transformation.
Smoking increases the risk of sleep apnea—and sleep apnea makes smoking harder to quit. The relationship is bidirectional, clinically significant, and almost never discussed in cessation support. Treating sleep disorders should be part of cessation care.
Smoking prevalence among homeless populations exceeds 70%—the highest of any demographic group. The cigarette is a coping mechanism for the most extreme stress, a currency in the street economy, and one of the last remaining pleasures for people who have lost almost everything.
Products
Select a product to view details, highlights, and technical specifications.
